Retatrutide Weight-Loss Research and FDA Status
Retatrutide is an investigational once-weekly molecule designed to activate GIP, GLP-1 and glucagon receptors. It is being studied in phase 3 trials but is not FDA-approved.

What is being studied?
The TRIUMPH program includes obesity and related-condition studies. Trial endpoints, selected participants and controlled monitoring should not be treated as a guarantee of real-world benefit or long-term safety.
ClinicalTrials.gov retatrutide study
How W8MD can help now
Patients do not need to wait for a future drug to receive evidence-based care. W8MD can compare currently approved weight-loss medications, nutrition, sleep treatment and non-medication plans using medical history, prior attempts, preferences, coverage and sustainable cost.
Discuss currently available options with W8MD
Brooklyn: 718-946-5500 · Northeast Philadelphia: 215-676-2334
Use the form only for a non-urgent callback request. Do not submit private medical, insurance, financial or other sensitive information.
Status reviewed September 4, 2026. Recheck FDA labeling and ClinicalTrials.gov before relying on this page.

